‘Viagra for the Brain’: Once-Daily Alzheimer’s Pill Slows Mental Decline by 31% in Major Trial

Joseph Benjamin
Published

An experimental once-daily tablet developed by South Korean pharmaceutical company AriBio has slowed the progression of Alzheimer’s disease by 31 per cent among a group of patients who received it without other dementia medications.

The drug, known as AR1001, delayed clinical decline by the equivalent of approximately 3.5 months over one year, according to results from a major phase III clinical trial presented at the Clinical Trials on Alzheimer’s Disease conference in Boston, United States.

The study involved 1,535 people with Alzheimer’s disease across 230 research sites in 13 countries, including the United Kingdom.

Participants in the monotherapy group, who took AR1001 without other dementia medications, performed 31 per cent better than those receiving a placebo on an assessment measuring memory, thinking abilities and everyday functioning.

However, when researchers included participants who were also taking other dementia medications, the reported benefit fell to 7 per cent. This result was not considered statistically significant.

Drug Uses an Ingredient From the Same Class as Viagra

AR1001 contains mirodenafil, which belongs to the same class of medicines as sildenafil, the active ingredient in Viagra, a drug used to treat erectile dysfunction.

Both medicines work by blocking an enzyme known as PDE5. This action relaxes blood vessels and increases blood flow.

Researchers believe AR1001 may have several effects in the brain, including reducing inflammation, improving blood circulation and protecting nerve cells.

The treatment works differently from existing disease-modifying Alzheimer’s drugs such as lecanemab and donanemab, which target and help remove amyloid plaques in the brain.

Unlike those treatments, which are administered through infusions or injections, AR1001 is being developed as a tablet taken once a day.

Results Could Offer an Alternative to Infusion-Based Treatments

The findings have drawn attention to the possibility of an oral treatment for Alzheimer’s that targets the underlying disease process rather than only managing symptoms.

Existing disease-modifying medicines, including lecanemab and donanemab, require administration through a clinic-based infusion or injection. They have not been approved for use on the NHS because of concerns about the high costs associated with providing them.

A tablet-based alternative could reduce the practical and financial demands of treatment while providing an option for patients who prefer not to receive injections.

However, AR1001 has not yet been approved for public use in the UK and must undergo assessment by the relevant regulatory authorities before it could become available.

Most Reported Side Effects Were Mild or Moderate

Researchers reported that most side effects experienced by participants during the trial were mild or moderate.

Diarrhoea, falls and dizziness were among the most frequently reported problems.

Around 69 per cent of participants receiving AR1001 experienced side effects, compared with 66.4 per cent of those given the placebo.

AriBio also examined Alzheimer’s-related markers in participants’ cerebrospinal fluid. The analysis identified lower levels of ptau217, a marker used to assess the presence of amyloid and tau, two proteins associated with the disease.

Alzheimer’s Society Welcomes Early Findings but Calls for Further Investigation

Dr Richard Oakley, Associate Director for Research and Innovation at Alzheimer’s Society, described the findings as an encouraging indication that AR1001 could become a treatment for early Alzheimer’s disease.

He said the results showed that the drug slowed the deterioration of memory and thinking abilities by nearly a third over the trial period.

However, Oakley noted that the reported benefit was not evident among participants taking other medications for Alzheimer’s symptoms, adding that the finding required further investigation.

He also highlighted the potential advantages of a once-daily tablet and said most reported side effects were mild to moderate.

Oakley stressed that AR1001 was still under development and was not available to the public. He also warned people against taking Viagra in an attempt to treat Alzheimer’s, explaining that AR1001 was being developed specifically for the disease.

He said further research was needed and that the full trial results would be important in determining the drug’s future.

US Neurologist Says More Treatment Options Are Needed

Dr David Greeley, a clinical researcher in Alzheimer’s drug development at Northwest Neurological in the United States, said the findings were encouraging for patients and families seeking additional treatment options.

Greeley, who has worked as a practising neurologist and clinical investigator for more than 30 years, has also been involved in AriBio’s research since the drug’s phase II trial.

He said the results from the study’s pre-specified monotherapy group supported further investigation of a once-daily oral treatment.

Greeley added that, if approved, the medicine could expand the choices available to patients, although further evaluation would be necessary to establish its effectiveness and affordability.

AriBio Says Its Goal Is Long-Term Oral Treatment

Dr Jai-Jun Choung, chairman and chief executive of AriBio, said the company began developing AR1001 with the aim of producing an oral medicine capable of slowing Alzheimer’s progression.

He said the company wanted to create a treatment that patients and their carers could use conveniently over an extended period.

Choung described the 31 per cent reduction in clinical decline among participants taking AR1001 alone as support for the drug’s potential as an alternative treatment approach.

He also thanked the patients, carers, investigators and clinical teams who participated in the international study.

Dementia Carers Together Appeal Funds Support for Unpaid Carers

The trial results come as the Daily Mail’s Dementia Carers Together Appeal raises money to support unpaid relatives and friends caring for people living with dementia.

The initiative is working with Alzheimer’s Society and the Mail Force charity to fund six-week courses across the UK.

The sessions are intended to provide carers with emotional and practical support, information about their rights and guidance on services available to them.

They will also give participants opportunities to meet others in similar circumstances and address the isolation, exhaustion and responsibilities that can follow a loved one’s dementia diagnosis.

The appeal aims to provide support to tens of thousands of unpaid dementia carers.

Donations can be made through the Mail Force Charity website, by text or by calling 0300 1234577. Cheques can also be sent to Dementia Carers Together, 42 Phoenix Court, Hawkins Road, Colchester CO2 8JY.

Spread the News. Share on
Facebook Twitter Reddit LinkedIn
Joseph Benjamin profile photo

About Joseph Benjamin